1003946-86-8

Basic information

• Product Name: (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate
• Synonyms: (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate
• CAS NO: 1003946-86-8
• Molecular Weight: 332.4
• Mol File: 1003946-86-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate(1003946-86-8)
• EPA Substance Registry System: (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate(1003946-86-8)

Safety Data

• Hazardous Substances Data: 1003946-86-8(Hazardous Substances Data)

Upstream product

• 2256715-14-5 (1s,5r)-6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester 
• 501-53-1 benzyl chloroformate 
• 2256715-14-5 trans-tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 1612172-51-6 (1R_.5S_.6s)-tert-butyl 6-(((benzyloxy)carbonyl)(methyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1003946-73-3 benzyl (1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-ylcarbamate 
• 1612172-56-1 benzyl N-((1R,5S,6s)-3-(4-((1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)carbamate 

Relevant articles and documents

Four and circular Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.

KINASE INHIBITOR AND USE THEREOF

The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.